Umeå University's logo

umu.sePublications
System disruptions
We are currently experiencing disruptions on the search portals due to high traffic. We are working to resolve the issue, you may temporarily encounter an error message.
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-6th-edition.csl
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Combination of gallium citrate and levofloxacin induces a distinct metabolome profile and enhances growth inhibition of multidrug-resistant Mycobacterium tuberculosis compared to linezolid
Umeå University, Faculty of Medicine, Department of Clinical Microbiology. Department of Microbiology, Virology and Biotechnology, Faculty of Biology, Odesa I.I. Mechnikov National University, Odesa, Ukraine.
Odesa Center for Socially Significant Diseases of Odesa Regional Council, Odesa, Ukraine.
Department of Microbiology, Virology and Biotechnology, Faculty of Biology, Odesa I.I. Mechnikov National University, Odesa, Ukraine.
Department of Microbiology, Virology and Biotechnology, Faculty of Biology, Odesa I.I. Mechnikov National University, Odesa, Ukraine.
Show others and affiliations
2024 (English)In: Frontiers in Microbiology, E-ISSN 1664-302X, Vol. 15, article id 1474071Article in journal (Refereed) Published
Abstract [en]

Introduction: Tuberculosis (TB) treatment typically involves a tailored combination of four antibiotics based on the drug resistance profile of the infecting strain. The increasing drug resistance of Mycobacterium tuberculosis (Mtb) requires the development of novel antibiotics to ensure effective treatment regimens. Gallium (Ga) is being explored as a repurposed drug against TB due to its ability to inhibit Mtb growth and disrupt iron metabolism. Given the potential interactions between Ga and established antibiotics, we investigated how a combination of Ga with levofloxacin (Lfx) or linezolid (Lzd) affects the growth and metabolome of a multidrug-resistant (MDR) Mtb clinical strain.

Methods: Mtb was cultured using a BACTEC 960 system with concentrations of Ga ranging from 125 to 1,000 μM and with 250 to 500 μM of Ga combined with 0.125 mg/L of Lfx or Lzd. For metabolome analysis, the antibacterials were used at concentrations that inhibited the growth of bacteria without causing cell death. Metabolites were extracted from Mtb cells and analyzed using chromatography-mass spectrometry.

Results: The MDR Mtb strain exhibited a dose-dependent response to Ga. Notably, the enhancement in growth inhibition was statistically significant for the Ga/Lfx combination compared to Ga alone, while no such significance was observed for Ga/Lzd. Moreover, exposure to Ga/Lfx or Ga/Lzd resulted in distinct metabolite profiles. Ga treatment increased the level of aconitate, fumarate, and glucose in the cells, suggesting the inhibition of iron-dependent aconitase and fumarate hydratase, as well as disruption of the pentose phosphate pathway. The levels of glucose, succinic acid, citric acid, and hexadecanoic acid followed a similar pattern in cells exposed to Ga and Ga/Lfx at 500 μM Ga but exhibited different trends at 250 μM Ga.

Discussion: In the presence of Lfx, the Mtb metabolome changes induced by Ga are more pronounced compared to those observed with Lzd. Lfx affects nucleic acids and transcription, which may enhance Ga-dependent growth inhibition by preventing the metabolic redirection that bacteria typically use to bypass iron-dependent enzymes.

Place, publisher, year, edition, pages
Frontiers Media S.A., 2024. Vol. 15, article id 1474071
Keywords [en]
levofloxacin, metabolome, drug resistance, central metabolism, Mycobacterium tuberculosis, gallium, linezolid, drug–drug interaction
National Category
Infectious Medicine Microbiology in the medical area
Identifiers
URN: urn:nbn:se:umu:diva-232554DOI: 10.3389/fmicb.2024.1474071ISI: 001379467900001PubMedID: 39697659Scopus ID: 2-s2.0-85212408140OAI: oai:DiVA.org:umu-232554DiVA, id: diva2:1917701
Funder
EU, European Research CouncilThe Kempe FoundationsScience for Life Laboratory, SciLifeLabAvailable from: 2024-12-03 Created: 2024-12-03 Last updated: 2025-01-08Bibliographically approved

Open Access in DiVA

fulltext(1988 kB)58 downloads
File information
File name FULLTEXT01.pdfFile size 1988 kBChecksum SHA-512
9757492a782c49dac8f4a9e8a0eea0c8fed715c362f7e17a4b68ae37390a83a8919d3ed3c0ad8213e4e724c5c1fdbb9820f9808618d7d0c18d2e42b1430e048e
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Ilchenko, OleksandrRamstedt, MadeleineRzhepishevska, Olena

Search in DiVA

By author/editor
Ilchenko, OleksandrRamstedt, MadeleineRzhepishevska, Olena
By organisation
Department of Clinical Microbiology
In the same journal
Frontiers in Microbiology
Infectious MedicineMicrobiology in the medical area

Search outside of DiVA

GoogleGoogle Scholar
Total: 58 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 210 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • apa-6th-edition.csl
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf